Hims & Hers Health, Inc. is under investigation following a lawsuit filed by the FTC and state authorities alleging the company misled consumers by charging for prescriptions immediately after intake forms and making subscription cancellations difficult. The FTC also claims Hims & Hers improperly shared consumers' health data with third parties like Meta and Snap. This legal action caused the company's stock to drop nearly 15% on July 29, 2026. Investors who suffered losses are encouraged to contact Kaplan Fox & Kilsheimer LLP, the law firm handling the securities investigation.
The FDA issued warnings to telehealth companies and compounding pharmacies about the use of unapproved compounded weight-loss drugs, including versions of semaglutide, tirzepatide, and retatrutide. Hims & Hers Health shares fell 3.2% following the an...
The Federal Trade Commission, along with California and Utah consumer protection agencies, sued Hims & Hers Health, Inc. for allegedly charging customers immediately after intake forms without clear disclosure and making subscription cancellations di...
